On 27th August 2017 a biopharmaceutical company Contravir pharmaceutical gets the new US patent issuance on the expansion program of the drug (CRV 431) Cyclophilin inhibitor used for the treatment of hepatitis B virus (HBV) with the US patent no. 9,741,271. The company also says that CRV 431 can also be used in conjunctions with the collaboration of tenofovir exalidex (TXL ™) which has its lead drug in phase 2 clinical trials in current scenario.
The patent has been added with the additional claims to the original patent of CRV 431 ; as we all know that cyclophilins are ubiquitous and are different in their cellular localization, enzymatic properties, and also in role for folding proteins; while cyclophilins also showers cure upon infectious diseases, inflammations, cell death, muscular dystrophy, ischemia reperfusion and also in oncogenesis. According to James Sapirstein, chief executive officer of Contravir pharmaceuticals – the issuance of new expansion of cyclophilin inhibitor program helps us in different aspects of disease treatment regarding to HBV and also in other departments , so having a patented portfolio of it helps us to access additional disease indications and to go to far extents than core program of hepatitis B viruses.
Company overview
As we all know that the Contravir pharmaceutical is a which has its kean interest on the developmental procedure of the antiviral diseases for its cure by using 3 different characterisation in their pipelines. One of them is the tenofovir exalidex (TXL ™) used to decrease systemic exposure i.e, low renal and bone side effects than Viread, while TXL is at the stage 2a of clinical research. The second is the CRV 431 with a unique structure which is used for the treatment of hepatitis B virus i.e, the cyclophilin inhibitor. The third category is for the Valnivudine ™ which is used orally and it is a nucleoside analog prodrugs helps in the treatment of herpes Zoster or shingles and it is currently in phase 3 of clinical research. It is also responsible for cure of the incidence of debilitating shingles-associated pain known as postherpetic neuralgia (PHN) in a phase 2 clinical research program .
What is CRV431 ?
CRV 431 is Cyclophilin Inhibitor which is a non-immunosuppressive analog of Cyclosporine A (CsA) which has a priority first for biochemical action in inhibition of cyclophilin isomerase activity and also plays an important role in protein folding. The cyclophilin shows its application in case of replication of the HIV-1 and HCV viruses; this inhibitor shows experimental models to complement current hepatitis B treatments by the reduction use of multiple markers of infectious characters like for example- HBV DNA, HBsAg, HBx, HBeAg, and HBV uptaken by the cells. Further report of the studies also suggests that CR V 431 possesses antifibrotic activity which may help in liver diseases in case of liver dysfunctioning patients.
Cyclophilin inhibition has been a target for the treatment of hepatitis C and other diseases, but the generation of potent, drug-like molecules through chemical synthesis has been challenging. In this study, a set of macrocyclic cyclophilin inhibitors was synthesized based on the core structure of the natural product sanglifehrin A. Initial compound optimization identified the valine-m-tyrosine-piperic acid tripeptide (Val-m-Tyr-Pip) in the sanglifehrin core, stereocenters at C14 and C15, and the hydroxyl group of the m-tyrosine (m-Tyr) residue as key contributors to compound potency. Replacing the C18-C21 diene unit of sanglifehrin with a styryl group led to potent compounds that displayed a novel binding mode in which the styrene moiety engaged in a π-stacking interaction with Arg 55 of cyclophilin A (Cyp A), and the m-Tyr residue was displaced into solvent. This observation allowed further simplifications of the scaffold to generate new lead compounds in the search for orally bioavailable cyclophilin inhibitors.
Structures of cyclophilin inhibitor proteins
Forward looking statement :-
The company Contravir is facing the problems regarding the forward looking statements like the “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others within the meaning of Private Securities Litigation Reform Act of 1995 and questions are being arises for the contradiction of the product and its materialistic reports with the results.There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.
As a result the company is looking forward to each and every aspects of the forward looking statements held on the press so that any litigation, regulation or any developmental flaws within the product of invention which could result in nullification .so the company is going through each and every points of allegations but though the investors should read the form 10-k thoroughly for any further and other periodic reports filed with the Securities and Exchange Commission.
